Guidelines issued by DoP for bulk drug parks

A brief guidelines for bulk drug parks and detailed guidelines will be released soon by
The Department of Pharmaceuticals (DoP), under the Ministry of Chemicals and Fertilisers, the Government of India. DoP has also announced the details of a financial assistance programme which includes grant-in-aid to three bulk drug parks with a total incentive of Rs 3000 crores for the construction of common infrastructure facilities.
Implementation of the proposed scheme will be done through a one time grant in aid and will be released in various phases for the creation of infrastructure in bulk drug to a State Implementing Agency.

The particular programme has a proposal to provide grant-in-aid to three bulk drug parks with a maximum limit of Rs 1000 crores per bulk drug park or 70 per cent of the project cost of common infrastructure facilities, as per the issued notification by Navdeep Rinwa, Joint Secretary, Department of Pharmaceuticals, .

The same notification also states that that in case of hilly regions and the North East Region, the grant-in-aid would be Rs 1000 crore per bulk drug park or 90 per cent of the project cost of common infrastructure facilities, whichever is less.

The proposed scheme would be helpful for infrastructure facilities like solvent recovery, distillation plant, central effluent treatment plant, common logistics facilities, advanced common testing centre, regulatory awareness facility centre, emergency response centre etc.

“We welcome the issued brief guidelines on bulk drug parks. The Himachal Pradesh Government is very keen on setting up the bulk drug park in the State with the help of the announced scheme by the Central Government. The State government is planning to acquire approximately 1350 acres of land, it has already identified 1000 bigha land and will be exploring the possibilities to acquire more land.” Dr Rajesh Gupta, a member of the Bulk Drug Park Committee, Himachal Pradesh and President, Himachal Drug Manufacturers Association (HDMA) told.

“We are reviewing the guidelines and will be discussing with the state industrial bodies.” said Ritu Sahay, Director-Drugs Controller, Jharkhand.

The proposal for application will be open from 2020-2021 to 2024-2025.

  • Related Posts

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

    Pak-made illegal cosmetics recovered from Itwari shop

    Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Pak-made illegal cosmetics recovered from Itwari shop

    Pak-made illegal cosmetics recovered from Itwari shop

    Licences of 20 medical stores suspended after inspections

    Licences of 20 medical stores suspended after inspections

    Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

    Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

    HP accounts for 47 inferior drugs in March alert

    HP accounts for 47 inferior drugs in March alert